Evommune, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EVMN | EDSA | EVAX | ALXO | EVGN | QTTB | |
|---|---|---|---|---|---|---|
| Market cap | 219.57M | 39.72M | 27.06M | 174.23M | 6.11M | 260.19M |
| P/E (TTM) | — | — | — | — | — | 2.8 |
| Forward P/E | -1.7 | — | -200.0 | -2.3 | -0.6 | -8.6 |
| Price/book | 0.8 | 71.7 | 2.6 | 1.3 | -1.6 | 2.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −69.11% | +38.19% | −50.96% | −25.88% | −70.31% | +111.14% |
| Today | −3.20% | −16.24% | −2.28% | +0.80% | +1.13% | +4.80% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All EVMN news ›Analysts Have Conflicting Sentiments on These NA Companies: Fiserv (FISV), SpyGlass Pharma (Nasdaq: SGP) and Evommune, Inc. (EVMN)
Analysts have been eager to weigh in on the NA sector with new ratings on Fiserv (FISV), SpyGlass Pharma (SGP) and Evommune, Inc. (EVMN). Wells Fargo analyst Jason Kupferberg maintained a Hold rating on Fiserv today and set a price target…
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
Nasdaq Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress Oct 1, 2026 8:00am EDT - Presentation highlights EVO301’s clear…
From articles in the 4Search news index.
In the news
Mentioned with
Most coverage from
-
markets.businessinsider.com1
-
nasdaq.com1
-
tradingview.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.